NCT06657560View on ClinicalTrials.gov

Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

July 3, 2025

Study Completion Date

July 3, 2025

Conditions

Contrast-Enhanced Magnetic Resonance Imaging Detection

Interventions

DRUG

HRS-9231

Trial Locations (1)

250014

Shandong First Medical University First Affiliated Hospital (Shandong Qianfoshan Hospital), Jinan

All Listed Sponsors

lead

Shanghai Shengdi Pharmaceutical Co., Ltd

INDUSTRY

NCT06657560 - Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function | Biotech Hunter | Biotech Hunter